CEO's and Governmen...
Health Care: Drugs
Cell Therapeutics Inc. (CTIC: NASDAQ)
$1.12 0.03 | 2.75%
02/08/12 - 04:00 PM ET
1.16M / 1.74M
Vol / Avg. Vol:1.11 / 1.09
Open / Prev. Close:1.10 - 1.12
Today's Range:0.95 - 3.33
52 Wk Range:-3.45%
Performance YTD:TheStreet Rating:
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserImagine!
- Userfrankiesun09@gmail.com
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
- Userbiotech121
- UserJswaim
- UserSLITraders
Latest CTIC Headlines from TheStreet
- The 5 Dumbest Things on Wall Street This Week: Feb. 3 02.03.12 | 06:02 am
- The 5 Dumbest Things on Wall Street: Feb. 3
02.03.12 | 05:02 am - Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 01.30.12 | 05:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- 22 Hot Drugs Facing FDA Approval in 2012 11.29.11 | 08:11 am
- 10 Best Mutual Funds for 2012 11.16.11 | 07:11 am
- Biotech Stock Mailbag: Exelixis 10.28.11 | 06:10 am
Press Releases for CTIC
- FDA's Oncologic Drugs Advisory Committee To Review Resubmitted Pixantrone New Drug Application On February 9, 2012 - PR Newswire 01.03.12 | 01:01 am
- Cell Therapeutics Retires Remaining Convertible Debt - PR Newswire 12.19.11 | 01:12 am
- Final OPAL Phase II Results Of Tosedostat Demonstrate Significant Response Rates In Elderly Patients With Treatment Refractory Or Relapsed Primary Or Secondary Acute Myeloid Leukemia (AML) - PR Newswire 12.13.11 | 01:12 am
- Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million Of Preferred Stock And Warrants - PR Newswire 12.09.11 | 01:12 am
- Tosedostat OPAL Study Final Results Selected For Oral Presentation At The 2011 American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.07.11 | 01:12 am
- FDA Sets April 24, 2012 As PDUFA Goal Date For Cell Therapeutics' Resubmitted Pixantrone New Drug Application - PR Newswire 12.06.11 | 01:12 am
- European Medicines Agency's (EMA) Committee For Human Medicinal Products (CHMP)Tentatively Scheduled To Render An Opinion On PixuvriTM Marketing Authorization Application On January 19, 2012 - PR Newswire 12.05.11 | 01:12 am
- U.S. Patent Office Issues Notice Of Allowance For Patent Application Related To CTI's GlycoPolymer Technology - PR Newswire 11.21.11 | 01:11 am
- Cell Therapeutics, Inc. Reports Results Of Annual Meeting Of Shareholders - PR Newswire 11.11.11 | 04:11 pm
- Cell Therapeutics Resubmits Pixantrone NDA To FDA For Consideration Of Accelerated Approval - PR Newswire 10.25.11 | 01:10 am
Partner Headlines for CTIC
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Cell Therapeutics Plummeting on NDA Withdrawl - Benzinga 01.30.12 | 09:01 am
- US Panel to Review CTIC's Pixantrone - Analyst Blog - Zacks 01.04.12 | 10:01 am
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal - NASDAQ 12.09.11 | 05:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- CTIC Loss Widens, Resubmits NDA - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Cell Therapeutics Efforts Validated - Analyst Blog - Zacks 10.07.11 | 04:10 pm
- Morning Market Movers - Benzinga 08.31.11 | 09:08 am
